Sentara Infusion Services, Chesapeake, VA

Is Sentara Infusion Services registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Sentara Infusion Services hold a Virginia pharmacy license?

State pharmacy license records for Virginia are not checked: the Department of Health Professions’ license lookup is an interactive search form, which this index does not use. This index reads only that state’s board actions.

Has Sentara Infusion Services had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Dec 16, 2022) for Sentara Infusion Services. State board actions: no Virginia Board of Pharmacy action under this exact name and city was found in the Virginia Department of Health Professions’ list of Board of Pharmacy case decisions from the last 90 days (actions dated Aug 17, 2026 to Nov 15, 2026) on Nov 15, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Sentara Infusion Services
Location
Chesapeake, VA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Nov 14, 2023
FDA Data Dashboard inspections
3 inspections: 2 OAI, 1 VAI; 2 published Form 483s
Form 483 text on this page
1 Form 483, 10 observations
State board records
Not checked (license records); board actions matched: 0

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Sentara Infusion Services, a 503A facility, with 2 dated actions.

Document
Nov 14, 2023Regulatory meetingRegulatory Meeting Held 11/14/2023Not linked by FDA
Dec 16, 2022Form 483483 Issued 12/16/2022FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Sentara Infusion Services, Chesapeake, VA (FEI number 3011627411), matched to this page by exact name, city and state. It lists 3 inspections: 2 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Dec 16, 2022Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30116274111193101
Aug 6, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30116274111064475
Jul 23, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3011627411936197

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 10 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Dec 5, 2022 to Dec 16, 2022: 10 observations

Firm on the cover
Sentara Infusion Services, 535 Independence Pkwy Ste 300, Chesapeake, VA 23320-5176
FEI number
3011627411
Establishment type on the cover
Producer of sterile drug products
FDA district office on the cover
11155 Dolfield Boulevard, Suite 117 Owings Mills, MD 21117
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.

Specifically,

A. The <Redacted B4> used inside the ISO 5 classified laminar airtlow hoods are not sterile. "The non-sterile wipes were observed being used as a disposable work surface (upon which items such as, but not limited to syringes, connectors, and IV bags with exposed ports were placed) and during cleaning operations. We observed: on December 5 and 7, 2022, Technician <Redacted B4>) used the non-sterile wipers as a disposable work surface on the ISO 5 work surface (for example, in the production of Rx <Redacted B4>, on December 7, 2022, Technician <Redacted B4> used the non-sterile wipers to clean a ISO 5 classitled work surtace; and on December 8, 2022, Technician <Redacted B4> wiped the interior of the ISO 5 classified hood with the non-sterile wipers.

B. The disinfectant contact time (also known as "dwell time") and coverage of items being disinfected were insufficient to achieve adequate level ls of disinfection. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Specifically, your conducts air and surface environmental sampling of your ISO classified areas every <Redacted B4>. In each environmental monitoring sampling performed since November 2020, actionable microbial contamination was identified, for example, in your ISO 7 classified areas, which contain ISO 5 classified hoods where drugs intended to be sterile are produced, as follows:

November 2020

- Buffer Room: Fungal Air Sample (6 cfu/m3) Penicillum sp. Exserhilum sp. Hormographiella sp.

- Anteroom: Fungal Air Sample ( 4 cfu/m3) Cladosporium sp. Geotrichium sp. r - <Redacted B4> Bacterial Air Sample (3 cfu/m3) Penicilum sp. Coagulase (-) Staphlococcus sp. Bacillus sp. rJ) :

April 2021

Buffer Room: Fungal Air Sample (3 cfu/m3) Trichoderma sp. Aspergillus sp.

October 2021

- Buffer Room: Bacterial Air Sample (3 cfu/m3) Aspergillus sp. Bacillus sp. Coagulase (-) Staphylococcus sp.

<Redacted B4> Room: Bacterial Air Sample (27 cfu/m3) Microbacterium sp. Coagulase (-) Staphylococcus Micrococcus sp.

I

Anteroom: Fungal Air Sample (2 cfu/m3) Verticillium sp.

April 2022

- Buffer Room: Bacterial Air Sample (4 cfu/m3) Chrysosporium sp. Micrococcus sp. ...

Read the full 483 (PDF on fda.gov)

Observation 3

You produced beta-lactam drugs without providing adequate cleaning of work surfaces to prevent cross-contamination.

Specifically, on December 7, 2022, we observed the production of the non-beta lactam drug product Caspofungin (Rx <Redacted B4>), after the production of Cefazohn Sodium 2000mg IV (Rx <Redacted B4>) Ertapenem (Inrvanz) Sodium GM NS Rx <Redacted B4> and Meropenem 500mg IN VS 125mL (Rx <Redacted B4>). During the production of these beta-lactam 1g products there was spillage on the ISO 5 classified work surface that was not deactivated during the technician's cleaning between products. The technician cleaned the beta-lactam products' spillage by wiping the exposed ISO 5 classified work surface of the laminar flow hood with a non-sterile wipe and sterile <Redacted B4>. You do not have a specific process to deactivate and remove any beta-lactam product spillage during your handling, processing, and filling operations.

Observation 4

Personnel engaged in aseptic processing were observed with exposed wlists and exposed hair.

Specifically,

A. On December 7, 2022, we observed Technician <Redacted B4> producing drug products intended to be sterile in the ISO 5 classified <Redacted B4> laminar airflow hoodw the exposed wrists, such as while producing Rx <Redacted B4> , Cefazolin 3gm in NS 1S0mL Homepump.

B. On December 12, 2022, we observed Technician <Redacted B4> working in the ISO 5 classified <Redacted B4> laminar airflow hood with exposed hair, for example, dunng the production of <Redacted B4> Mitrimone Lactate 52mg in 0.45% NS 65mL.

Observation 5

Materials or supplies were not disinfected prior to entering the aseptic processing areas.

Specifically, on December 5, 6, 7, and 8, 2022, during the production of drug products intended to be sterile, for example, but not limited to, Rx <Redacted B4> <Redacted B4> Rx <Redacted B4> Rx <Redacted B4> Rx <Redacted B4> and <Redacted B4>

Technicians brought materials, such as component vials, syringe pouches, and IV bags, from the ISO 7 classified buffer room into the ISO 5 classified laminar flow hoods, without disinfecting the outer smfaces of the materials. We observed technicians <Redacted B4> and <Redacted B4> use these materials without sanitizing their outer surfaces. Furthermore, these matenals ant plastlc totes were not disinfected when placed in the <Redacted B4> when introducing materials from the unclassified <Redacted B4> room into the ISO 7 classified buffer room. Similarly, the <Redacted B4> automated compounding device ACDT hand-held barcode scanner was introduced into the ISO 5 classified Iaminar flow hood after resting on the stock cart adjacent to the hood in the ISO 7 classified buffer room, without sanitizing the outer surface and the cord of the barcode scanner.

Observation 6

Personnel conducted aseptic manipulations and placed equipment/supplies in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.

Specifically,

A. On December 6, 2022, in the ISO 5 classified <Redacted B4> laminar flow hood, we observed purportedly sterile connections being made to setup the automatic compounding device and replace empty component product vials, in front of other component materials and the metal vial rack, blocking first pass air. Furthermore, we observed the connection to the finished product bag being made in front of hanging IV component bags, blocking first pass air.

B. On December 12, 2022. in the ISO 5 classified <Redacted B4> laminar flow hood, Technician <Redacted B4> punctured the septum of components while blocking first pass air with a gloved hand during the production of Ampicillin/Sulbactam 12gm in NS 600mL (Rx <Redacted B4>)

C. ...

Read the full 483 (PDF on fda.gov)

Observation 7

The ISO 5 classified aseptic processing areas had difficult to clean and visibly dirty equipment or surface.

Specifically,

A. On December 5, 6, 7, 8, and 9, 2022, we observed dark, orange-colored (rust-like) spots on the <Redacted B4> vial rack in ISO 5 classified <Redacted B4> laminar airflow hood <Redacted B4> used in the production of all total parenteral nutrition (TPN) products. rne vial rack is situated in the path of first-pass air, between the rear HEP A diffuser screen and where we observed connections were made to component vials, hanging IV bags, and the finished product bag. The dark, orange-colored (rust-like) spots were not removed before or in between production of all TPN products, such as, but not limited to Rx <Redacted B4> and Rx <Redacted B4>

B. On December 7 and 12, 2022 we observed <Redacted B4> laminar airflow hoods <Redacted B4> had cracked and difficult to clean surfaces between the left <Redacted B4> stainless-steel panel and the hood worksurface. ...

Read the full 483 (PDF on fda.gov)

Observation 8

Personnel touched equipment or other surfaces located outside of the ISO 5 classified aseptic processing area with gloved hands and then engaged in aseptic processing without changing or sanitizing gloves.

Specifically,

A. On December 5, 6, and 7, 2022, technicians repeatedly reached back and forth between the ISO 5 classified laminar airflow hoods and items in the ISO 7 classified buffer room, without cleaning or sanitizing gloved hands, and resuming pmportedly sterile production operations. Items in the ISO 7 classified buffer room included trash cans, wrapped syringes and connectors, pens, markers, calculators, bins, chairs, a phone, production log papers (non-autoclavable), and a barcode scanner. Fmthennore, items were obtained from the stock carts located outside the ISO 5 classified laminar flow hoods and brought into the hoods without disinfecting the outer surfaces of those items.

B. On December 5, 6, and 7, 2022, technicians touched non-sterile gowning, such as bouffant caps, frocks, and disposable face masks, with gloved hands and engaged in sterile production without changing or sanitizing their gloves.

C. ...

Read the full 483 (PDF on fda.gov)

Observation 9

Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.

Specifically,

A. For example, the media fills were not representative of container-closure types (for example, syringes, elastomeric pumps, large N bags), the quantity and volume of finished drug products per order, and equipment (for example, <Redacted B4> automated compounding device, repeater pump).

B. The plates and media used in enviromnental monitoring sample testing performed in November 2022 were incubated for <Redacted B4> prior to reading. The <Redacted B4> plates used in fingertip sampling and the media-filled bag samples have a procedurally required incubation time off <Redacted B4> and <Redacted B4>, respectively.

Observation 10

IS0-5 classified areas were not certified under dynamic conditions.

Specifically, unidirectional airflow was not verified under dynamic operational conditions representative of your typical aseptic processing practices. Air visualization studies ("smoke studies") conducted in October 2021 , April 2022, and October 2022 in your ISO 5 classified laminar airflow hoods did not demonstrate the movement of first pass air around equipment, supplies, or operator manipulations as observed during sterile production operations.

A. In one hood <Redacted B4> which is designated for use in the production of all total parenteral nurition (TPN) products we observed hanging IV bags and component vials mounted on the metal vial rack of the <Redacted B4> ® automatic compounding device (ACD). The metal vial rack consists of approximatey <Redacted B4> poles, and with the ACD, occupies approximately <Redacted B4> of the width of the respective hood. Additionally, component bags are hung on the bar within the hood. ...

Read the full 483 (PDF on fda.gov)

Linked 483s whose text is not shown

State board of pharmacy records

State pharmacy license records for Virginia are not checked: the Department of Health Professions’ license lookup is an interactive search form, which this index does not use. This index reads only that state’s board actions. Board actions source.

What this covers: Board of Pharmacy case decisions the Department of Health Professions lists as entered in the last 90 days, worded as it gives them. Older decisions are reachable only through a search form, which this index does not use, so only that 90-day window is checked. The orders themselves sit behind a disclaimer form and are not linked. Virginia pharmacy licenses are not checked. Actions in the data are dated Aug 17, 2026 to Nov 15, 2026.

Same name at other locations

FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.